Veropharm, one of Russia's largest drug makers, saw its 2010 IFRS net profit increase by 9 percent year on year, to 1.2 billion rubles ($42.85 million), the company said on Thursday.
The company's sales jumped 23 percent to 5.395 billion rubles, while EBITDA rose 15 percent to 1.601 billion rubles in 2010, the company said in a statement.
The EBITDA margin edged down to 29.7 percent in 2010 from 31.6 percent in 2009.
Veropharm's fixed capital investment increased by 116 percent in 2010 to 170.2 million rubles, while the company's debt fell by 53 percent to 464.8 million rubles.
The share of Veropharm's prescription drugs in 2010 grew to 70 percent from 69 percent a year earlier and the proportion of non-prescription drugs went up to 13 percent from 12 percent.
Veropharm's sales under the state-backed additional drug supply program amounted to 171.4 million rubles or 3.2% of the company's overall sales last year.
MOSCOW, May 19 (RIA Novosti)
